Valganciclovir
Valganciclovir is an orally active antiviral agent. Valganciclovir can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir can be used for the research of Cytomegalovirus.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 175865-60-8
- Formel: C14H22N6O5
- Molecular Weight:354.36
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-16305
Maribavir -
HY-A0032A
Valganciclovir hydrochloride -
HY-17438
Cidofovir -
HY-16305R
Maribavir (Standard) -
HY-15233
Letermovir -
HY-15523
Braco-19 -
HY-109528
Fomivirsen sodium -
HY-108261
Tomeglovir -
HY-A0032AR
Valganciclovir hydrochloride (Standard) -
HY-108261R
Tomeglovir (Standard) -
HY-14532
Brincidofovir -
HY-N1127
Tricin
Biologische Aktivität
Beschreibung
In Vitro
Valganciclovir (500 μM, 5-7 days) inhibits the growth of human adenoviruses (Ads) in A549 cells[1].
Valganciclovir (0.003-10 mM, 10 min) with ganciclovir (HY-13637) inhibits the uptake of glycylsarcosine in Caco-2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:5 days, 7days
-
Result:Showed EC50 values ranged from 120.5 μM (Ad4) to 244.4 μM (Ad6). Showed IC50 values was calculated to be 11.74 mM at 7 days post-infection.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunosuppressed hamsters[1]
-
Dosage:200 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Resulted in significantly smaller magnitude of weight loss for all groups.
Reduced the liver pathology.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 175865-60-8
-
Molecular Weight 354.36
-
Formel C14H22N6O5
-
SMILES
N[C@@H](C(C)C)C(OCC(OCN1C=NC2=C1N=C(N)NC2=O)CO)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Toth K, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters [J]. Viruses, 2015, 7(3): 1409-1428. [Content Brief]
[2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. [Content Brief]
[3]. Cvetkovic R S, et al. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients [J]. Drugs, 2005, 65: 859-878. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Valganciclovir Related Classifications
HY-A0032 Related Classifications
Powered by Bioz